Document is current

Article History

Received: 23 August 2021

Accepted: 3 February 2022

First Online: 22 February 2022

Declarations

:

: The patient-derived cancer xenograft models which data are included in the EurOPDX Data Portal have been established in strict compliance with applicable national, European, and international laws. In particular, the use of human samples for PDX establishment was approved by ethics committees relevant to PDX owners (Candiolo Cancer Institute, Italy: Comitato Etico IRCCS di Candiolo; TRACE PDX Platform, KU Leuven, Belgium: Ethics Committee Research UZ/KU Leuven; Carlos Caldas Laboratory, University of Cambridge: NHS Cambridgeshire 2 Research Ethics Committee; Institut Curie: Comité de Revue Institutionnel de l’Institut Curie, Département Santé de la Direction Générale de la Recherche et de l’Innovation du Ministère de l’Enseignement Supérieur et de la Recherche (DGRI/5); Vall d’Hebron Institute of Oncology: Comité Etico de Investigación Clínica del Hospital Universitario Vall d’Hebron; Netherlands Cancer Institute: NKI-AVL Institutional Review Board; University of Manchester: NHS Tameside and& Glossop Local Research Ethics Committee or Manchester Cancer Research Centre Biobank Management Board; University Medical Center Groningen: Medische Ethische Toetsingscommissie van het UMCG; Luxembourg Institute of Health: Comité National d’Ethique de Recherche (CNER)). The written consent or non-opposition of the patients was obtained, and a separate written consent was obtained for sequencing where required. In certain countries, ‘non-opposition’ was sufficient to allow the use of human samples for research purposes at the time some of the models were established, as approved by the ethics committee, however, written consent has since then been generalized.

: Not applicable.

: The authors declare that they have no competing interests.